Table 3.
Risk factors of teicoplanin ADRs among patients who previously experienced vancomycin ADRs
| Characteristic | ADR to teicoplanin |
p value | |
|---|---|---|---|
| No (n = 183) | Yes (n = 55) | ||
| Age, yr | 60.1 ± 16.5 | 57.9 ± 17.6 | 0.388 |
| Sex | 0.262 | ||
| Male | 112 (61.2) | 29 (52.7) | |
| Female | 71 (38.8) | 26 (47.3) | |
| Daily dose of teicoplanin, mg/kg | 12.3 ± 3.8 | 12.6 ± 3.4 | 0.596 |
| Duration of teicoplanin use | 15.0 ± 11.7 | 9.5 ± 8.2 | 0.002 |
| Type of vancomycin hypersensitivity | |||
| Skin reaction (n = 84) | 61 (33.3) | 23 (41.8) | 0.248 |
| Neutropenia (n = 74) | 54 (29.5) | 20 (36.4) | 0.335 |
| Drug fever (n = 63) | 42 (23.0) | 21 (38.2) | 0.025 |
| Thrombocytopenia (n = 18) | 15 (8.2) | 3 (5.5) | 0.500 |
| Eosinophilia (n = 7) | 4 (2.2) | 3 (5.5) | 0.208 |
| Others (n = 9) | 8 (4.4) | 1 (1.8) | 0.384 |
| Acute kidney injury (n = 30) | 28 (15.3) | 2 (3.6) | 0.022 |
| History of hypersensitivity reaction to other drugs | 29 (15.8) | 16 (29.1) | 0.028 |
Values are presented as mean ± SD or number (%).
ADR, adverse drug reaction.